A new oral form of Wegovy, a weight-loss medication containing semaglutide, was recently approved for use in the United Kingdom, marking a significant development in obesity treatment. Wegovy, previously available only as a once-weekly injection, now comes in a daily pill, offering an alternative for patients who are reluctant to use injectable medications. This treatment belongs to a new class of drugs that mimic the GLP-1 hormone, which helps reduce appetite.

The pill is approved for adults with a body mass index (BMI) of 30 or higher, or those with a BMI between 27 and 30 who have weight-related health conditions such as heart disease, hypertension, or sleep apnoea. Private clinics in the UK are beginning to offer the pill, but it is not yet available through the National Health Service (NHS). Discussions between the manufacturer, Novo Nordisk, and UK government officials are reportedly ongoing regarding potential NHS availability, with price being a key consideration.

In the United States, where the Wegovy pill has been accessible since January, patients have reported positive outcomes. Rebecca Walker, 47, from Nevada, said she lost over 15 pounds within two months after switching from no treatment to the pill, noting improvements in energy levels and a renewed ability to exercise. Similarly, David Clarke from New York described decreased food cravings since starting the medication three weeks ago, marking a notable change in his long-term struggle with weight.

Experts caution, however, that the pill’s effectiveness depends largely on strict adherence to its dosing instructions. The drug must be taken after an eight-hour fast, followed by a 30-minute wait before eating or drinking to ensure proper absorption. Failure to follow these steps may reduce its appetite-suppressing benefits. Side effects are generally similar to those seen with the injection form, including nausea, fatigue, gastrointestinal discomfort, and, in rare cases, pancreatitis. Patients report that side effects tend to diminish after the initial weeks of treatment.

Regarding cost, the pill is expected to be less expensive than the injectable version due to lower production costs, although prices vary among providers. For example, some UK pharmacies have listed the pill at comparable prices to the injection—around £199 per month—while in the US, the pill’s highest dose costs approximately £225 monthly, slightly less than injections. Compared to other weight-loss medications like Mounjaro, which typically costs about £300 per month, Wegovy pills may offer a more affordable option.

While the pill appears to have a slightly lower average weight-loss efficacy compared to injections (14 percent versus 15 percent of body weight), experts emphasize that this difference is marginal at higher doses. However, it remains less potent than Mounjaro, which is linked to around 20 percent average weight loss. Some specialists suggest that the pill’s slower and possibly less intensive effects may suit patients who prefer gradual weight reduction.

Weight-loss experts underline the importance of dietary changes alongside medication to maximize results. Studies indicate that a significant proportion of patients experience plateaus or minimal weight loss, and many regain weight upon stopping treatment. Nutritional guidance focusing on increased protein, fiber, and healthy fats is recommended to support sustained outcomes.

Overall, the introduction of the Wegovy pill provides an additional tool in weight management, potentially improving accessibility and adherence for some patients. Ongoing evaluations will determine how it integrates into broader clinical practice and public health programs.